Pharma BD Deal Intelligence

Ironwood Pharmaceuticals, Inc. / VectivBio Holding AG

2023 · Acquisition/Merger · $1.0B · Complete

Ironwood entered a definitive agreement to acquire VectivBio for $17.00/share, total consideration ~$1B net of cash and debt, gaining apraglutide, a Phase 3 GLP-2 analog for SBS-IF positioned as a potential best-in-class follow-on to Linzess. Tender offer with HSR clearance.

Key facts

• Announced May 22, 2023
• Closed Jun 26, 2023
• Deal value $1.0B
• Deal type Acquisition/Merger
• Therapeutic area Short bowel syndrome with intestinal failure (SBS-IF)
• Indications Short bowel syndrome with intestinal failure (SBS-IF)
• Key assets Apraglutide — long-acting GLP-2 analog
• Mechanism GLP-2 receptor agonist (next-generation, weekly dosing)

← Browse all deals  ·  How we score deals